USHATE Academy Ivan-Penchev, Department of Endocrinology, Medical University-Sofia, Sofia, Bulgaria.
USHATE Academy Ivan-Penchev, Department of Endocrinology, Medical University-Sofia, Sofia, Bulgaria.
Ann Endocrinol (Paris). 2020 Feb;81(1):3-10. doi: 10.1016/j.ando.2020.01.001. Epub 2020 Jan 25.
Carbohydrate disorders are the most frequent metabolic disorders, affecting a significant proportion of patients with pheochromocytoma.
A retrospective study assessed the prevalence and progression of carbohydrate disorders in 204 patients (92 men, 112 women) with histologically proven pheochromocytoma diagnosed in a single specialized tertiary center during a 40-year period (1978-2017). One hundred were followed-up after tumor removal.
Carbohydrate disorders were diagnosed in 49.5% of cases: 30.4% with diabetes and, 19.1% prediabetes. Subjects with carbohydrate disorders had significantly greater age at diagnosis and higher 24-hour urine metanephrine and normetanephrine concentrations than those with normal glucose tolerance. One-third of patients with diabetes achieved good glycemic control under oral treatment (54% on metformin monotherapy). One-third of patients overall required preoperative insulin treatment. Postoperative follow-up (100 patients; 5-year mean duration) showed reduced prevalence of diabetes (13% vs. 33%; P=0.0007) and prediabetes (12% vs. 24%; P=0.027). Almost 60% of subjects initially diagnosed with carbohydrate disorders recovered normal glucose tolerance after surgery; these subjects had significantly higher preoperative urine metanephrine/normetanephrine levels than those with persistent diabetes/prediabetes. Correlation analysis revealed a moderate negative relationship between urine metanephrine/normetanephrine concentration and the outcome of the carbohydrate disorders (Spearmen's Rho=-0.507; P=0.013). There was no significant difference according to pre- or postoperative prevalence of obesity (15% vs. 16%; P=0.845) or dyslipidemia (46% vs. 39%; P=0.316).
Carbohydrate disorders affect approximately 50% of pheochromocytoma patients; 30% develop overt diabetes, which may be the only clinical manifestation in some rare cases. Pheochromocytoma-related diabetes is more likely to affect patients with predominant adrenaline secretion. It is often easy to control and usually requires oral antidiabetic treatment. Reversibility of carbohydrate disorders depend on severity, preoperative metanephrine level, age and weight.
碳水化合物代谢紊乱是最常见的代谢紊乱,影响着相当一部分嗜铬细胞瘤患者。
本回顾性研究评估了在一家专门的三级中心的 40 年期间(1978-2017 年)诊断的 204 例(92 例男性,112 例女性)组织学证实的嗜铬细胞瘤患者中碳水化合物代谢紊乱的患病率和进展情况。其中 100 例在肿瘤切除后进行了随访。
49.5%的病例诊断为碳水化合物代谢紊乱:30.4%为糖尿病,19.1%为糖尿病前期。与糖耐量正常者相比,碳水化合物代谢紊乱患者的诊断年龄更大,24 小时尿间甲肾上腺素和去甲肾上腺素浓度更高。三分之一的糖尿病患者在口服治疗下(54%的患者接受二甲双胍单药治疗)血糖控制良好。总体而言,三分之一的患者需要术前胰岛素治疗。术后随访(100 例患者;平均 5 年)显示糖尿病(33%降至 13%;P=0.0007)和糖尿病前期(24%降至 12%;P=0.027)的患病率降低。近 60%最初诊断为碳水化合物代谢紊乱的患者术后恢复正常糖耐量;这些患者的术前尿间甲肾上腺素/去甲肾上腺素水平明显高于持续糖尿病/糖尿病前期患者。相关性分析显示,尿间甲肾上腺素/去甲肾上腺素浓度与碳水化合物代谢紊乱的结果呈中度负相关(Spearmen's Rho=-0.507;P=0.013)。根据术前或术后肥胖(15%与 16%;P=0.845)或血脂异常(46%与 39%;P=0.316)的患病率,并无显著差异。
碳水化合物代谢紊乱影响约 50%的嗜铬细胞瘤患者;其中 30%发展为显性糖尿病,在某些罕见病例中,这可能是唯一的临床表现。嗜铬细胞瘤相关糖尿病更可能影响以肾上腺素分泌为主的患者。它通常易于控制,通常需要口服抗糖尿病治疗。碳水化合物代谢紊乱的可逆性取决于严重程度、术前间甲肾上腺素水平、年龄和体重。